Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult to treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the shelf universal cell-based delivery platform is designed to protect, amplify and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety.
